Expertise in
1
conditions

Belinda Yeo

145 Studley Rd, 
Heidelberg, VIC, AU 
Expertise in
1
conditions
145 Studley Rd, 
Heidelberg, VIC, AU 

Overview

Belinda Yeo practices practicing medicine in Heidelberg, Australia.

Ms. Yeo is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, Menopause, and Mastectomy.

She is actively involved in clinical research, co-authoring 60 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

145 Studley Rd, Heidelberg, VIC 3084, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

60 Total Publications

Real-World Feasibility Assessment of Short-Course Preoperative Endocrine Therapy Using the Ki67 Biomarker in an Australian Cohort of Patients With Estrogen Receptor-Positive Early Breast Cancer.
Real-World Feasibility Assessment of Short-Course Preoperative Endocrine Therapy Using the Ki67 Biomarker in an Australian Cohort of Patients With Estrogen Receptor-Positive Early Breast Cancer.
Journal: Clinical breast cancer
Published: April 13, 2026

Frequently Asked Questions about Belinda Yeo

Is Belinda Yeo a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Belinda Yeo is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Belinda Yeo participate in research or clinical trials?

Yes. Belinda Yeo has published 60 articles and abstracts on conditions like Breast Cancer. You can view a list of Belinda Yeo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Yeo's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile